Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Linda Kaplan who wrote (2726)	11/20/1997 6:01:00 PM
From: Bruce Olsten	Read Replies (1) \| Respond to of 23519

To Gene Voss: Do you have the patent for the ED gel being developed by Machrochem as well as the VVUS intra-urethral patent? Also, is the HVSF intra-urethral product a violation of your patent, or has that yet to be determined? I am looking at as many ED solution companies as I can as I feel the potential for profit will skyrocket! <<< potence ointment Inventors: Voss; Gene (213 Alcade Moreno, San Antonio, TX 78232); Eichler; Allen C. (1347 Lockhill-Selma, San Antonio, TX 78213). Appl. No.: 20,544Filed: Mar. 2,1987Intl. Cl. : A61K 31/47, A61K 31/50Current U.S. Cl.: 514/248; 514/307;514/400; 514/502; 514/649; 514/947Field of Search: 514/307, 400, 248, 502, 649 ---------------------------------------------------------------------- U.S. Patent Documents 1,176,597Mar., 1916Pictet2,561,071Jul., 1951Prisk128/2603,795,675Mar., 1974Laguzzi260/2833,966,724Jun., 1976Hughes et al.260/2474,018,927Apr.,1977Vorhees514/3074,055,648Oct., 1977Sache424/2604,117,841Oct.,1978Perrotta et al.128/1554,311,707Jan., 1982Birnbaum et al.514/5304,564,010Jan., 1986Coughlan et al.128/156 Primary Examiner: Schenkman; Leonard Attorney, Agent or Firm: Gunn, Lee & Jackson Abstract An ointment for relieving impotence. The ointment generally consists of a primary agent, a carrier, and a base, and is applied directly to the penis. The primary agent is a vasodilator selected from the group consisting of papaverine, hydralazine, sodium nitroprusside, phenoxybenzamine and phentolamine. The carrier is used to assist absorption of the primary agent through the skin around the penis. When the primary agent enters the corpora cavernosa within the penis, it causes dilation of the corpora, resulting in an erection. >>>

To: Linda Kaplan who wrote (2726)	11/20/1997 6:04:00 PM
From: david	Respond to of 23519

I still think VVUS will stay in check at least tommorrow, i.e., it will be traded around 25 due to the heavy call positions of 25 and higher. probably, today's move has already reflected partial short covering and many other shorts know that MM will let it go much higher than 25 before tommorrow so they would wait for next week. IMO, next week if we get one day like today with, say, more than 2 million shares, then watch out, the real short squeeze will happen and VVUS will all the way go back to 30+. where is Leo ? I wonder if he has already covered all his short positions. d.